4.7 Article

An insight into crosstalk among multiple signaling pathways contributing to epileptogenesis

Journal

EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 910, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.ejphar.2021.174469

Keywords

Epileptogenesis; mTOR; PI3K/Akt; MAP/ERK; cAMP JAK-STAT; Wnt/beta-catenin; c-jun/JNK

Ask authors/readers for more resources

Despite years of research, epilepsy still affects a large number of individuals and current drugs do not target the underlying pathophysiology. Recent studies focus on various signaling pathways such as mTOR and Wnt to understand epileptogenesis. Further investigation is needed to explore the potential of targeting these pathways for future epilepsy therapies.
Despite the years of research, epilepsy remains uncontrolled in one-third of afflicted individuals and poses a health and economic burden on society. Currently available anti-epileptic drugs mainly target the excitatoryinhibitory imbalance despite targeting the underlying pathophysiology of the disease. Recent research focuses on understanding the pathophysiologic mechanisms that lead to seizure generation and on possible new treatment avenues for preventing epilepsy after a brain injury. Various signaling pathways, including the mechanistic target of rapamycin (mTOR) pathway, mitogen-activated protein kinase (MAP-ERK) pathway, JAK-STAT pathway, wnt/beta-catenin signaling, cAMP pathway, and jun kinase pathway, have been suggested to play an essential role in this regard. Recent work suggests that the mTOR pathway intervenes epileptogenesis and proposes that mTOR inhibitors may have antiepileptogenic properties for epilepsy. In the same way, several animal studies have indicated the involvement of the Wnt signaling pathway in neurogenesis and neuronal death induced by seizures in different phases (acute and chronic) of seizure development. Various studies have also documented the activation of JAK-STAT signaling in epilepsy and cAMP involvement in epileptogenesis through CREB (cAMP response element-binding protein). Although studies are there, the mechanism for how components of these pathways mediate epileptogenesis requires further investigation. This review summarises the current role of various signaling pathways involved in epileptogenesis and the crosstalk among them. Furthermore, we will also discuss the mechanical base for the interaction between these pathways and how these interactions could be a new emerging promising target for future epilepsy therapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

Neuroprotective effect of Nrf2 activator dimethyl fumarate, on the hippocampal neurons in chemical kindling model in rat

Neha Singh, Sheekha Vijayanti, Lekha Saha, Alka Bhatia, Dibyajyoti Banerjee, Amitava Chakrabarti

EPILEPSY RESEARCH (2018)

Article Pharmacology & Pharmacy

Potentiation of Pentylenetetrazole-induced neuronal damage by dimethyl sulfoxide in chemical kindling model in rats

Puja Kumari, Neha Singh, Lekha Saha

INDIAN JOURNAL OF PHARMACOLOGY (2018)

Article Neurosciences

Effect of dimethyl fumarate on neuroinflammation and apoptosis in pentylenetetrazol kindling model in rats

Neha Singh, Lekha Saha, Puja Kumari, Jagjit Singh, Alka Bhatia, Dibyajyoti Banerjee, Amitava Chakrabarti

BRAIN RESEARCH BULLETIN (2019)

Article Pharmacology & Pharmacy

Study of nuclear factor-2 erythroid related factor-2 activator, berberine, in paclitaxel induced peripheral neuropathy pain model in rats

Jagjit Singh, Lekha Saha, Neha Singh, Puja Kumari, Alka Bhatia, Amitava Chakrabarti

JOURNAL OF PHARMACY AND PHARMACOLOGY (2019)

Review Neurosciences

A review on preventive role of ketogenic diet (KD) in CNS disorders from the gut microbiota perspective

Kajal Rawat, Neha Singh, Puja Kumari, Lekha Saha

Summary: The gut microbiota plays a crucial role in neurological diseases through the gut-brain axis, with factors such as diet and stress affecting colonization patterns. Recent studies have shown that the ketogenic diet can remodel the gut microbiome and have protective effects on CNS disorders. Understanding the interaction between gut microbes and KD may provide novel therapeutic approaches for neurological disorders.

REVIEWS IN THE NEUROSCIENCES (2021)

Review Pharmacology & Pharmacy

COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies

Kajal Rawat, Puja Kumari, Lekha Saha

Summary: COVID-19, caused by a new strain of betacoronavirus named as SARS-CoV-2, poses a huge burden on public health and global economies due to its high transmission rate. Developing vaccines is essential for preventing the spread of the virus and reducing mortality.

EUROPEAN JOURNAL OF PHARMACOLOGY (2021)

Article Cell Biology

L-Methionine prevents β-cell damage by modulating the expression of Arx, MafA and regulation of FOXO1 in type 1 diabetic rats

Umashanker Navik, Kajal Rawat, Kulbhushan Tikoo

Summary: In this study, we investigated the effect of L-Methionine (L-Met) on streptozotocin-induced beta-cell damage model of diabetes mellitus in rats. Our results showed that L-Met improved plasma glucose and insulin levels, increased insulin expression, and inhibited the expression of Arx. Furthermore, L-Met regulated the expression of FOXO1 through histone methylation marks H3K27me3 and H3K4me3. These findings suggest that L-Met may be a potential therapeutic approach for preventing beta-cell injury in diabetes.

ACTA HISTOCHEMICA (2022)

Review Neurosciences

What is the Role of Lithium in Epilepsy?

Sree Lalitha Bojja, Neha Singh, Kiran Kumar Kolathur, Chamallamudi Mallikarjuna Rao

Summary: Lithium is a well-known medication for bipolar and mood disorders, and recent studies have shown its neuroprotective and neurotrophic effects in various neurological diseases. However, the exact mechanisms of its actions, especially in epilepsy treatment, are still unknown.

CURRENT NEUROPHARMACOLOGY (2022)

No Data Available